Aveo Pharmaceuticals, Inc.

Alisa C Bell

William M Winston, Jr

Heidi Okamura

Ronan O'Hagan

Jeno Gyuris

Sandra Abbott

Samantha Perino

Kelly Kreuter

Hamid Tissire

Laura L Poling

H Heidi Okamura

Jeanine Lorusso

Monoclonal antibodies that bind and inhibit activation of human Notch3 are disclosed. The antibodies can be used to treat cell proliferative diseases and disorders, including certain forms of cancer, associated with activation and/or overexpression of Notch3.

Anti-Notch3 antibody

Monoclonal antibodies that bind and inhibit activation of human Notch3 are disclosed. The antibodies can be used to treat cell proliferative diseases and disorders, including certain forms of cancer, associated with activation of Notch3.

Anti-notch3 antibodies

Anti-NOTCH3 antibodies

Anti-Notch3 antibodies

The disclosure provides a method for identifying cancer tissue sensitive to treatment with an inhibitor of Notch receptor activation. The method comprises determining the level of HeyL gene expression in a sample derived from the cancer tissue, wherein an elevated level of HeyL gene expression alone in the sample indicates sensitivity to the cancer tissue to treatment with an inhibitor of Notch receptor activation.

Identifying cancers sensitive to treatment with inhibitors of notch signaling

Growing community of inventors

Bedford, MA, United States of America

Alisa C Bell